Histone modification therapy of cancer

Advances in Genetics

Volumn 70, Issue C, 2010, Pages 341-386

  Biancotto, Chiara ^a   Frigè, Gianmaria ^a   Minucci, Saverio ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE METHYLTRANSFERASE; ENZYME INHIBITOR; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE; METHYLTRANSFERASE; PRMT2 PROTEIN, HUMAN; PROTEIN ARGININE METHYLTRANSFERASE; SIGNAL PEPTIDE;

ACETYLATION; ANIMAL; BOOK; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; GENETIC EPIGENESIS; HUMAN; METABOLISM; METHYLATION; NEOPLASM; PROTEIN PROCESSING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; NEOPLASMS;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONE DEMETHYLASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; METHYLATION; METHYLTRANSFERASES; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-ARGININE N-METHYLTRANSFERASES;

EID: 77957333749     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-380866-0.60013-7     Document Type: Book

References (227)

1. Ait-Si-Ali S., Polesskaya A., Filleur S., Ferreira R., Duquet A., Robin P., Vervish A., Trouche D., Cabon F., Harel-Bellan A. CBP/p300 histone acetyl-transferase activity is important for the G1/S transition. Oncogene 2000, 19(20):2430-2437.
2. Allis C.D., Berger S.L., Cote J., Dent S., Jenuwien T., Kouzarides T., Pillus L., Reinberg D., Shi Y., Shiekhattar R., et al. New nomenclature for chromatin-modifying enzymes. Cell 2007, 131(4):633-636.
3. Arany Z., Sellers W.R., Livingston D.M., Eckner R. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 1994, 77(6):799-800.
4. Avvakumov N., Cote J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 2007, 26(37):5395-5407.
5. Ayroldi E., Blasi E., Varesio L., Wiltrout R.H. Inhibition of proliferation of retrovirus-immortalized macrophages by LPS and IFN-gamma: Possible autocrine down-regulation of cell growth by induction of IL1 and TNF. Biotherapy 1992, 4(4):267-276.
6. Bacon C.L., Gallagher H.C., Haughey J.C., Regan C.M. Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase. J. Neurochem. 2002, 83(1):12-19.
7. Balasubramanyam K., Altaf M., Varier R.A., Swaminathan V., Ravindran A., Sadhale P.P., Kundu T.K. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 2004, 279(32):33716-33726.
8. Balasubramanyam K., Varier R.A., Altaf M., Swaminathan V., Siddappa N.B., Ranga U., Kundu T.K. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 2004, 279(49):51163-51171.
9. Bandyopadhyay D., Okan N.A., Bales E., Nascimento L., Cole P.A., Medrano E.E. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res. 2002, 62(21):6231-6239.
10. Bannister A.J., Miska E.A., Gorlich D., Kouzarides T. Acetylation of importin-alpha nuclear import factors by CBP/p300. Curr. Biol. 2000, 10(8):467-470.
11. Bannister A.J., Zegerman P., Partridge J.F., Miska E.A., Thomas J.O., Allshire R.C., Kouzarides T. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 2001, 410(6824):120-124.
12. Barrett A., Madsen B., Copier J., Lu P.J., Cooper L., Scibetta A.G., Burchell J., Taylor-Papadimitriou J. PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: A new cancer/testis antigen?. Int. J. Cancer 2002, 101(6):581-588.
13. Bar-Sela G., Epelbaum R., Schaffer M. Curcumin as an Anti-Cancer Agent: Review of the Gap between Basic and Clinical Applications. Curr. Med. Chem. 2010, 17(3):190-197.
14. Barski A., Cuddapah S., Cui K., Roh T.Y., Schones D.E., Wang Z., Wei G., Chepelev I., Zhao K. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129(4):823-837.
15. Batova A., Shao L.E., Diccianni M.B., Yu A.L., Tanaka T., Rephaeli A., Nudelman A., Yu J. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 2002, 100(9):3319-3324.
16. Bayes M., Rabasseda X., Prous J.R. Gateways to clinical trials. Methods Find Exp. Clin. Pharmacol. 2007, 29(7):467-509.
17. Biel M., Kretsovali A., Karatzali E., Papamatheakis J., Giannis A. Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angew. Chem. Int. Ed Engl. 2004, 43(30):3974-3976.
18. Binda C., Valente S., Romanenghi M., Pilotto S., Cirilli R., Karytinos A., Ciossani G., Botrugno O.A., Forneris F., Tardugno M., et al. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J. Am. Chem. Soc. 2010, 132(19):6827-6833.
19. Bonfils C., Kalita A., Dubay M., Siu L.L., Carducci M.A., Reid G., Martell R.E., Besterman J.M., Li Z. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin. Cancer Res. 2008, 14(11):3441-3449.
20. Borrow J., Stanton V.P., Andresen J.M., Becher R., Behm F.G., Chaganti R.S., Civin C.I., Disteche C., Dube I., Frischauf A.M., et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat. Genet. 1996, 14(1):33-41.
21. Bradbury C.A., Khanim F.L., Hayden R., Bunce C.M., White D.A., Drayson M.T., Craddock C., Turner B.M. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005, 19(10):1751-1759.
22. Brownell J.E., Zhou J., Ranalli T., Kobayashi R., Edmondson D.G., Roth S.Y., Allis C.D. Tetrahymena histone acetyltransferase A: A homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 1996, 84(6):843-851.
23. Bug G., Ritter M., Wassmann B., Schoch C., Heinzel T., Schwarz K., Romanski A., Kramer O.H., Kampfmann M., Hoelzer D., et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005, 104(12):2717-2725.
24. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., Richon V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000, 60(18):5165-5170.
25. Butler L.M., Webb Y., Agus D.B., Higgins B., Tolentino T.R., Kutko M.C., LaQuaglia M.P., Drobnjak M., Cordon-Cardo C., Scher H.I., et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. 2001, 7(4):962-970.
26. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., Lin T.S., Liu S., Sklenar A.R., Davis M.E., et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105(3):959-967.
27. Calame K.L., Lin K.I., Tunyaplin C. Regulatory mechanisms that determine the development and function of plasma cells. Annu. Rev. Immunol. 2003, 21:205-230.
28. Camphausen K., Tofilon P.J. Inhibition of histone deacetylation: A strategy for tumor radiosensitization. J. Clin. Oncol. 2007, 25(26):4051-4056.
29. Carducci M.A., Nelson J.B., Chan-Tack K.M., Ayyagari S.R., Sweatt W.H., Campbell P.A., Nelson W.G., Simons J.W. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res. 1996, 2(2):379-387.
30. Cedar H., Bergman Y. Linking DNA methylation and histone modification: Patterns and paradigms. Nat. Rev. Genet. 2009, 10(5):295-304.
31. Chaffanet M., Gressin L., Preudhomme C., Soenen-Cornu V., Birnbaum D., Pebusque M.J. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosom. Cancer 2000, 28(2):138-144.
32. Champagne N., Bertos N.R., Pelletier N., Wang A.H., Vezmar M., Yang Y., Heng H.H., Yang X.J. Identification of a human histone acetyltransferase related to monocytic leukemia zinc finger protein. J. Biol. Chem. 1999, 274(40):28528-28536.
33. Chan H.M., La Thangue N.B. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell Sci. 2001, 114(Pt. 13):2363-2373.
34. Chang Y., Zhang X., Horton J.R., Upadhyay A.K., Spannhoff A., Liu J., Snyder J.P., Bedford M.T., Cheng X. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat. Struct. Mol. Biol. 2009, 16(3):312-317.
35. Chen W.Y., Wang D.H., Yen R.C., Luo J., Gu W., Baylin S.B. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005, 123(3):437-448.
36. Cheng D., Yadav N., King R.W., Swanson M.S., Weinstein E.J., Bedford M.T. Small molecule regulators of protein arginine methyltransferases. J. Biol. Chem. 2004, 279(23):23892-23899.
37. Cheung N., Chan L.C., Thompson A., Cleary M.L., So C.W. Protein arginine-methyltransferase-dependent oncogenesis. Nat. Cell Biol. 2007, 9(10):1208-1215.
38. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325(5942):834-840.
39. Cimino G., Lo-Coco F., Fenu S., Travaglini L., Finolezzi E., Mancini M., Nanni M., Careddu A., Fazi F., Padula F., et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res. 2006, 66(17):8903-8911.
40. Cinatl J., Kotchetkov R., Blaheta R., Driever P.H., Vogel J.U., Cinatl J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: Enhancement by combination with interferon-alpha. Int. J. Oncol. 2002, 20(1):97-106.
41. Cloos P.A., Christensen J., Agger K., Maiolica A., Rappsilber J., Antal T., Hansen K.H., Helin K. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006, 442(7100):307-311.
42. Coffey D.C., Kutko M.C., Glick R.D., Butler L.M., Heller G., Rifkind R.A., Marks P.A., Richon V.M., La Quaglia M.P. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 2001, 61(9):3591-3594.
43. Cozzio A., Passegue E., Ayton P.M., Karsunky H., Cleary M.L., Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003, 17(24):3029-3035.
44. Culhane J.C., Cole P.A. LSD1 and the chemistry of histone demethylation. Curr. Opin. Chem. Biol. 2007, 11(5):561-568.
45. Dalgliesh G.L., Furge K., Greenman C., Chen L., Bignell G., Butler A., Davies H., Edkins S., Hardy C., Latimer C., et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463(7279):360-363.
46. Davis C.A., Haberland M., Arnold M.A., Sutherland L.B., McDonald O.G., Richardson J.A., Childs G., Harris S., Owens G.K., Olson E.N. PRISM/PRDM6, a transcriptional repressor that promotes the proliferative gene program in smooth muscle cells. Mol. Cell. Biol. 2006, 26(7):2626-2636.
47. Dhordain P., Lin R.J., Quief S., Lantoine D., Kerckaert J.P., Evans R.M., Albagli O. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res. 1998, 26(20):4645-4651.
48. DiGiuseppe J.A., Weng L.J., Yu K.H., Fu S., Kastan M.B., Samid D., Gore S.D. Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: Structure-function analysis. Leukemia 1999, 13(8):1243-1253.
49. Ding L., Erdmann C., Chinnaiyan A.M., Merajver S.D., Kleer C.G. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res. 2006, 66(8):4095-4099.
50. Doyon Y., Cayrou C., Ullah M., Landry A.J., Cote V., Selleck W., Lane W.S., Tan S., Yang X.J., Cote J. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol. Cell 2006, 21(1):51-64.
51. Duvic M., Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today 2007, 43(9):585-599.
52. Emenaker N.J., Calaf G.M., Cox D., Basson M.D., Qureshi N. Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model. J. Nutr. 2001, 131(11 Suppl.):3041S-3046S.
53. Engel D., Nudelman A., Levovich I., Gruss-Fischer T., Entin-Meer M., Phillips D.R., Cutts S.M., Rephaeli A. Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines. J. Cancer Res. Clin. Oncol. 2006, 132(10):673-683.
54. Entin-Meer M., Yang X., VandenBerg S.R., Lamborn K.R., Nudelman A., Rephaeli A., Haas-Kogan D.A. In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro-oncology 2007, 9(2):82-88.
55. Fantin V.R., Loboda A., Paweletz C.P., Hendrickson R.C., Pierce J.W., Roth J.A., Li L., Gooden F., Korenchuk S., Hou X.S., et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 2008, 68(10):3785-3794.
56. Fears S., Mathieu C., Zeleznik-Le N., Huang S., Rowley J.D., Nucifora G. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc. Natl Acad. Sci. USA 1996, 93(4):1642-1647.
57. Feng Q., Wang H., Ng H.H., Erdjument-Bromage H., Tempst P., Struhl K., Zhang Y. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr. Biol. 2002, 12(12):1052-1058.
58. Finch J.T., Lutter L.C., Rhodes D., Brown R.S., Rushton B., Levitt M., Klug A. Structure of nucleosome core particles of chromatin. Nature 1977, 269(5623):29-36.
59. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401(6749):188-193.
60. Fournel M., Bonfils C., Hou Y., Yan P.T., Trachy-Bourget M.C., Kalita A., Liu J., Lu A.H., Zhou N.Z., Robert M.F., et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther. 2008, 7(4):759-768.
61. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37(4):391-400.
62. Funabiki T., Kreider B.L., Ihle J.N. The carboxyl domain of zinc fingers of the Evi-1 myeloid transforming gene binds a consensus sequence of GAAGATGAG. Oncogene 1994, 9(6):1575-1581.
63. Furumai R., Matsuyama A., Kobashi N., Lee K.H., Nishiyama M., Nakajima H., Tanaka A., Komatsu Y., Nishino N., Yoshida M., et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002, 62(17):4916-4921.
64. Galanis E., Jaeckle K.A., Maurer M.J., Reid J.M., Ames M.M., Hardwick J.S., Reilly J.F., Loboda A., Nebozhyn M., Fantin V.R., et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: A north central cancer treatment group study. J. Clin. Oncol. 2009, 27(12):2052-2058.
65. Gao L., Cueto M.A., Asselbergs F., Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 2002, 277(28):25748-25755.
66. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., Rytting M., Wierda W.G., Ravandi F., Koller C., et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108(10):3271-3279.
67. Garcia-Manero G., Assouline S., Cortes J., Estrov Z., Kantarjian H., Yang H., Newsome W.M., Miller W.H., Rousseau C., Kalita A., et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112(4):981-989.
68. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., Faderl S., Koller C., Morris G., Rosner G., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111(3):1060-1066.
69. Gargiulo G., Minucci S. Epigenomic profiling of cancer cells. Int. J. Biochem. Cell Biol. 2009, 41(1):127-135.
70. Gargiulo G., Levy S., Bucci G., Romanenghi M., Fornasari L., Beeson K.Y., Goldberg S.M., Cesaroni M., Ballarini M., Santoro F., et al. NA-Seq: A discovery tool for the analysis of chromatin structure and dynamics during differentiation. Dev. Cell 2009, 16(3):466-481.
71. Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K., Chin S.F., Daigo Y., Russell P., Wilson A., Sowter H.M., et al. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 2000, 24(3):300-303.
72. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26(37):5420-5432.
73. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
74. Goel A., Kunnumakkara A.B., Aggarwal B.B. Curcumin as "Curecumin": From kitchen to clinic. Biochem. Pharmacol. 2008, 75(4):787-809.
75. Gojo I., Jiemjit A., Trepel J.B., Sparreboom A., Figg W.D., Rollins S., Tidwell M.L., Greer J., Chung E.J., Lee M.J., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007, 109(7):2781-2790.
76. Gore S.D., Weng L.J., Zhai S., Figg W.D., Donehower R.C., Dover G.J., Grever M., Griffin C.A., Grochow L.B., Rowinsky E.K., et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 2001, 7(8):2330-2339.
77. Greiner D., Bonaldi T., Eskeland R., Roemer E., Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 2005, 1(3):143-145.
78. Grignani F., De Matteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., Fanelli M., Ruthardt M., Ferrara F.F., Zamir I., et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998, 391(6669):815-818.
79. Guidez F., Howell L., Isalan M., Cebrat M., Alani R.M., Ivins S., Hormaeche I., McConnell M.J., Pierce S., Cole P.A., et al. Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein. Mol. Cell. Biol. 2005, 25(13):5552-5566.
80. Gyory I., Fejer G., Ghosh N., Seto E., Wright K.L. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J. Immunol. 2003, 170(6):3125-3133.
81. Halkidou K., Gaughan L., Cook S., Leung H.Y., Neal D.E., Robson C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004, 59(2):177-189.
82. He L.Z., Guidez F., Tribioli C., Peruzzi D., Ruthardt M., Zelent A., Pandolfi P.P. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat. Genet. 1998, 18(2):126-135.
83. He L.Z., Tolentino T., Grayson P., Zhong S., Warrell R.P., Rifkind R.A., Marks P.A., Richon V.M., Pandolfi P.P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 2001, 108(9):1321-1330.
84. Hess-Stumpp H., Bracker T.U., Henderson D., Politz O. MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int. J. Biochem. Cell Biol. 2007, 39(7-8):1388-1405.
85. Hilfiker A., Hilfiker-Kleiner D., Pannuti A., Lucchesi J.C. mof, a putative acetyl transferase gene related to the Tip60 and MOZ human genes and to the SAS genes of yeast, is required for dosage compensation in Drosophila. EMBO J. 1997, 16(8):2054-2060.
86. Hinnebusch B.F., Meng S., Wu J.T., Archer S.Y., Hodin R.A. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J. Nutr. 2002, 132(5):1012-1017.
87. Hrzenjak A., Moinfar F., Kremser M.L., Strohmeier B., Staber P.B., Zatloukal K., Denk H. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Ther. 2006, 5(9):2203-2210.
88. Huang B.H., Laban M., Leung C.H., Lee L., Lee C.K., Salto-Tellez M., Raju G.C., Hooi S.C. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005, 12(4):395-404.
89. Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., et al. p53 is regulated by the lysine demethylase LSD1. Nature 2007, 449(7158):105-108.
90. Huang Y., Stewart T.M., Wu Y., Baylin S.B., Marton L.J., Perkins B., Jones R.J., Woster P.M., Casero R.A. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin. Cancer Res. 2009, 15(23):7217-7228.
91. Huffman D.M., Grizzle W.E., Bamman M.M., Kim J.S., Eltoum I.A., Elgavish A., Nagy T.R. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007, 67(14):6612-6618.
92. Iizuka M., Stillman B. Histone acetyltransferase HBO1 interacts with the ORC1 subunit of the human initiator protein. J. Biol. Chem. 1999, 274(33):23027-23034.
93. Ikura T., Ogryzko V.V., Grigoriev M., Groisman R., Wang J., Horikoshi M., Scully R., Qin J., Nakatani Y. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 2000, 102(4):463-473.
94. Itoh Y., Suzuki T., Miyata N. Isoform-selective histone deacetylase inhibitors. Curr. Pharm. Des. 2008, 14(6):529-544.
95. Jenuwein T. Re-SET-ting heterochromatin by histone methyltransferases. Trends Cell Biol. 2001, 11(6):266-273.
96. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293(5532):1074-1080.
97. Johannessen C.U., Johannessen S.I. Valproate: Past, present, and future. CNS Drug Rev. 2003, 9(2):199-216.
98. Kahl P., Gullotti L., Heukamp L.C., Wolf S., Friedrichs N., Vorreuther R., Solleder G., Bastian P.J., Ellinger J., Metzger E., et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006, 66(23):11341-11347.
99. Kalkhoven E., Roelfsema J.H., Teunissen H., den Boer A., Ariyurek Y., Zantema A., Breuning M.H., Hennekam R.C., Peters D.J. Loss of CBP acetyltransferase activity by PHD finger mutations in Rubinstein-Taybi syndrome. Hum. Mol. Genet. 2003, 12(4):441-450.
100. Kamine J., Elangovan B., Subramanian T., Coleman D., Chinnadurai G. Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. Virology 1996, 216(2):357-366.
101. Kanazawa I. Short review on monoamine oxidase and its inhibitors. Eur. Neurol. 1994, 34(Suppl. 3):36-39.
102. Kell J. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer. Curr. Opin. Investig. Drugs 2007, 8(6):485-492.
103. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S.C., Carey N., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409(2):581-589.
104. Kim Y.B., Lee K.H., Sugita K., Yoshida M., Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 1999, 18(15):2461-2470.
105. Kim K.C., Geng L., Huang S. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res. 2003, 63(22):7619-7623.
106. Kim Y.H., Whittaker S., Demierre M.F., Rook A.H., Lerner A., Duvic M., Reddy S., Kim E.J., Robak T., Becker J.C., et al. Clinically significant responses achieved with romidepsin in treatment-refractory cutaneous T-cell lymphoma: final results from a Phase 2B, International, multicenter, registration study. ASH Annual Meeting Abstracts 2008.
107. Kirschbaum M., Zain J., Popplewell L., Pullarkat V., Obadike N., Frankel P., Zwiebel J., Forman S., Newman E., Gandara D. Phase 2 study of suberoylanilide hydroxamic acid (SAHA) in relapsed or refractory indolent non-Hodgkin lymphoma: A California Cancer Consortium study. J. Clin. Oncol. (Meeting Abstracts) 2007, 25:18515.
108. Klimek V.M., Fircanis S., Maslak P., Guernah I., Baum M., Wu N., Panageas K., Wright J.J., Pandolfi P.P., Nimer S.D. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res. 2008, 14(3):826-832.
109. Kondo Y., Shen L., Suzuki S., Kurokawa T., Masuko K., Tanaka Y., Kato H., Mizuno Y., Yokoe M., Sugauchi F., et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol. Res. 2007, 37(11):974-983.
110. Kondo Y., Shen L., Ahmed S., Boumber Y., Sekido Y., Haddad B.R., Issa J.P. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS ONE 2008, 3(4):e2037.
111. Kondo Y., Shen L., Cheng A.S., Ahmed S., Boumber Y., Charo C., Yamochi T., Urano T., Furukawa K., Kwabi-Addo B., et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 2008, 40(6):741-750.
112. Konstantinopoulos P.A., Vandoros G.P., Papavassiliou A.G. FK228 (depsipeptide): A HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother. Pharmacol. 2006, 58(5):711-715.
113. Kouzarides T. Histone methylation in transcriptional control. Curr. Opin. Genet. Dev. 2002, 12(2):198-209.
114. Kuendgen A., Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007, 110(5):943-954.
115. Lahortiga I., Agirre X., Belloni E., Vazquez I., Larrayoz M.J., Gasparini P., Lo Coco F., Pelicci P.G., Calasanz M.J., Odero M.D. Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. Oncogene 2004, 23(1):311-316.
116. Lau O.D., Kundu T.K., Soccio R.E., Ait-Si-Ali S., Khalil E.M., Vassilev A., Wolffe A.P., Nakatani Y., Roeder R.G., Cole P.A. HATs off: Selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol. Cell 2000, 5(3):589-595.
117. Lehrmann H., Pritchard L.L., Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. 2002, 86:41-65.
118. Lemercier C., Brocard M.P., Puvion-Dutilleul F., Kao H.Y., Albagli O., Khochbin S. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J. Biol. Chem. 2002, 277(24):22045-22052.
119. Letunic I., Copley R.R., Schmidt S., Ciccarelli F.D., Doerks T., Schultz J., Ponting C.P., Bork P. SMART 4.0: Towards genomic data integration. Nucleic Acids Res. 2004, 32(Database issue):D142-144.
120. Lim S., Janzer A., Becker A., Zimmer A., Schule R., Buettner R., Kirfel J. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010, 31(3):512-520.
121. Liu L., Shao G., Steele-Perkins G., Huang S. The retinoblastoma interacting zinc finger gene RIZ produces a PR domain-lacking product through an internal promoter. J. Biol. Chem. 1997, 272(5):2984-2991.
122. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., Lu L., Irvin D., Black K.L., Yu J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5:67.
123. Lucas D.M., Davis M.E., Parthun M.R., Mone A.P., Kitada S., Cunningham K.D., Flax E.L., Wickham J., Reed J.C., Byrd J.C., et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004, 18(7):1207-1214.
124. Lund A.H., van Lohuizen M. Epigenetics and cancer. Genes Dev. 2004, 18(19):2315-2335.
125. Mai A., Altucci L. Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead. Int. J. Biochem. Cell Biol. 2009, 41(1):199-213.
126. Mai A., Massa S., Rotili D., Cerbara I., Valente S., Pezzi R., Simeoni S., Ragno R. Histone deacetylation in epigenetics: An attractive target for anticancer therapy. Med. Res. Rev. 2005, 25(3):261-309.
127. Mai A., Valente S., Cheng D., Perrone A., Ragno R., Simeoni S., Sbardella G., Brosch G., Nebbioso A., Conte M., et al. Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors. ChemMedChem 2007, 2(7):987-991.
128. Mai A., Cheng D., Bedford M.T., Valente S., Nebbioso A., Perrone A., Brosch G., Sbardella G., De Bellis F., Miceli M., et al. epigenetic multiple ligands: Mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. J. Med. Chem. 2008, 51(7):2279-2290.
129. Majumder S., Liu Y., Ford O.H., Mohler J.L., Whang Y.E. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. Prostate 2006, 66(12):1292-1301.
130. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12(10):1247-1252.
131. Mantelingu K., Reddy B.A., Swaminathan V., Kishore A.H., Siddappa N.B., Kumar G.V., Nagashankar G., Natesh N., Roy S., Sadhale P.P., et al. Specific inhibition of p300-HAT alters global gene expression and represses HIV replication. Chem. Biol. 2007, 14(6):645-657.
132. Marks P.A. Discovery and development of SAHA as an anticancer agent. Oncogene 2007, 26(9):1351-1356.
133. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst. 2000, 92(15):1210-1216.
134. Marks P.A., Richon V.M., Breslow R., Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 2001, 13(6):477-483.
135. Martin C., Zhang Y. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 2005, 6(11):838-849.
136. Martinez-Garcia E., Licht J.D. Deregulation of H3K27 methylation in cancer. Nat. Genet. 2010, 42(2):100-101.
137. Melchior S.W., Brown L.G., Figg W.D., Quinn J.E., Santucci R.A., Brunner J., Thuroff J.W., Lange P.H., Vessella R.L. Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. Int. J. Oncol. 1999, 14(3):501-508.
138. Metzger E., Wissmann M., Yin N., Muller J.M., Schneider R., Peters A.H., Gunther T., Buettner R., Schule R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005, 437(7057):436-439.
139. Michan S., Sinclair D. Sirtuins in mammals: Insights into their biological function. Biochem. J. 2007, 404(1):1-13.
140. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6(1):38-51.
141. Minucci S., Nervi C., Lo Coco F., Pelicci P.G. Histone deacetylases: A common molecular target for differentiation treatment of acute myeloid leukemias?. Oncogene 2001, 20(24):3110-3115.
142. Miotto B., Struhl K. HBO1 histone acetylase is a coactivator of the replication licensing factor Cdt1. Genes Dev. 2008, 22(19):2633-2638.
143. Miura T.A., Cook J.L., Potter T.A., Ryan S., Routes J.M. The interaction of adenovirus E1A with p300 family members modulates cellular gene expression to reduce tumorigenicity. J. Cell. Biochem. 2007, 100(4):929-940.
144. Morgunkova A., Barlev N.A. Lysine methylation goes global. Cell Cycle 2006, 5(12):1308-1312.
145. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42(2):181-185.
146. Morishita K., Parker D.S., Mucenski M.L., Jenkins N.A., Copeland N.G., Ihle J.N. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988, 54(6):831-840.
147. Muraoka M., Konishi M., Kikuchi-Yanoshita R., Tanaka K., Shitara N., Chong J.M., Iwama T., Miyaki M. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996, 12(7):1565-1569.
148. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., Alvarez R., Schiavone E.M., Ferrara F., Bresciani F., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 2005, 11(1):77-84.
149. Nielsen S.J., Schneider R., Bauer U.M., Bannister A.J., Morrison A., O'Carroll D., Firestein R., Cleary M., Jenuwein T., Herrera R.E., et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 2001, 412(6846):561-565.
150. Odenike O.M., Alkan S., Sher D., Godwin J.E., Huo D., Brandt S.J., Green M., Xie J., Zhang Y., Vesole D.H., et al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin. Cancer Res. 2008, 14(21):7095-7101.
151. Okada Y., Takeda S., Tanaka Y., Belmonte J.C., Hirokawa N. Mechanism of nodal flow: A conserved symmetry breaking event in left-right axis determination. Cell 2005, 121(4):633-644.
152. Olsen E.A., Kim Y.H., Kuzel T.M., Pacheco T.R., Foss F.M., Parker S., Frankel S.R., Chen C., Ricker J.L., Arduino J.M., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 2007, 25(21):3109-3115.
153. Osada H., Tatematsu Y., Saito H., Yatabe Y., Mitsudomi T., Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int. J. Cancer 2004, 112(1):26-32.
154. Ozdag H., Teschendorff A.E., Ahmed A.A., Hyland S.J., Blenkiron C., Bobrow L., Veerakumarasivam A., Burtt G., Subkhankulova T., Arends M.J., et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006, 7:90.
155. Paik W.K., Kim S. Enzymatic demethylation of calf thymus histones. Biochem. Biophys. Res. Commun. 1973, 51(3):781-788.
156. Paik W.K., Kim S. Epsilon-alkyllysinase. New assay method, purification, and biological significance. Arch. Biochem. Biophys. 1974, 165(1):369-378.
157. Pal S., Vishwanath S.N., Erdjument-Bromage H., Tempst P., Sif S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol. Cell. Biol. 2004, 24(21):9630-9645.
158. Pan M.H., Chang W.L., Lin-Shiau S.Y., Ho C.T., Lin J.K. Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells. J. Agric. Food Chem. 2001, 49(3):1464-1474.
159. Panagopoulos I., Fioretos T., Isaksson M., Samuelsson U., Billstrom R., Strombeck B., Mitelman F., Johansson B. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Hum. Mol. Genet. 2001, 10(4):395-404.
160. Peters A.H., O'Carroll D., Scherthan H., Mechtler K., Sauer S., Schofer C., Weipoltshammer K., Pagani M., Lachner M., Kohlmaier A., et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001, 107(3):323-337.
161. Phillips A.C., Vousden K.H. Acetyltransferases and tumour suppression. Breast Cancer Res. 2000, 2(4):244-246.
162. Piekarz R.L., Robey R., Sandor V., Bakke S., Wilson W.H., Dahmoush L., Kingma D.M., Turner M.L., Altemus R., Bates S.E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood 2001, 98(9):2865-2868.
163. Piscitelli S.C., Thibault A., Figg W.D., Tompkins A., Headlee D., Lieberman R., Samid D., Myers C.E. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J. Clin. Pharmacol. 1995, 35(4):368-373.
164. Pruitt K., Zinn R.L., Ohm J.E., McGarvey K.M., Kang S.H., Watkins D.N., Herman J.G., Baylin S.B. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006, 2(3):e40.
165. Qian C., Zhou M.M. SET domain protein lysine methyltransferases: Structure, specificity and catalysis. Cell. Mol. Life Sci. 2006, 63(23):2755-2763.
166. Qian D.Z., Wei Y.F., Wang X., Kato Y., Cheng L., Pili R. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate 2007, 67(11):1182-1193.
167. Qian X., Ara G., Mills E., LaRochelle W.J., Lichenstein H.S., Jeffers M. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int. J. Cancer 2008, 122(6):1400-1410.
168. Rea S., Eisenhaber F., O'Carroll D., Strahl B.D., Sun Z.W., Schmid M., Opravil S., Mechtler K., Ponting C.P., Allis C.D., et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000, 406(6796):593-599.
169. Reid T., Valone F., Lipera W., Irwin D., Paroly W., Natale R., Sreedharan S., Keer H., Lum B., Scappaticci F., et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 2004, 45(3):381-386.
170. Rice J.C., Allis C.D. Histone methylation versus histone acetylation: New insights into epigenetic regulation. Curr. Opin. Cell Biol. 2001, 13(3):263-273.
171. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., Marks P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl Acad. Sci. USA 1998, 95(6):3003-3007.
172. Robertson K.D., Ait-Si-Ali S., Yokochi T., Wade P.A., Jones P.L., Wolffe A.P. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 2000, 25(3):338-342.
173. Roth S.Y., Denu J.M., Allis C.D. Histone acetyltransferases. Annu. Rev. Biochem. 2001, 70:81-120.
174. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., Figg W.D., Hwang K., Chung E.J., Murgo A., et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 2005, 23(17):3912-3922.
175. Sanchez R., Zhou M.M. The role of human bromodomains in chromatin biology and gene transcription. Curr. Opin Drug Discov. Devel. 2009, 12(5):659-665.
176. Sarma K., Reinberg D. Histone variants meet their match. Nat. Rev. Mol. Cell Biol. 2005, 6(2):139-149.
177. Satake N., Ishida Y., Otoh Y., Hinohara S., Kobayashi H., Sakashita A., Maseki N., Kaneko Y. Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation. Genes Chromosom. Cancer 1997, 20(1):60-63.
178. Schiltz R.L., Mizzen C.A., Vassilev A., Cook R.G., Allis C.D., Nakatani Y. Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates. J. Biol. Chem. 1999, 274(3):1189-1192.
179. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 2007, 39(2):232-236.
180. Schmidt D.M., McCafferty D.G. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 2007, 46(14):4408-4416.
181. Schulte J.H., Lim S., Schramm A., Friedrichs N., Koster J., Versteeg R., Ora I., Pajtler K., Klein-Hitpass L., Kuhfittig-Kulle S., et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: Implications for therapy. Cancer Res. 2009, 69(5):2065-2071.
182. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435(7046):1262-1266.
183. Shaffer A.L., Rosenwald A., Staudt L.M. Lymphoid malignancies: The dark side of B-cell differentiation. Nat. Rev. Immunol. 2002, 2(12):920-932.
184. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141(1):69-80.
185. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., Casero R.A. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119(7):941-953.
186. Shiama N. The p300/CBP family: Integrating signals with transcription factors and chromatin. Trends Cell Biol. 1997, 7(6):230-236.
187. Shiio Y., Eisenman R.N. Histone sumoylation is associated with transcriptional repression. Proc. Natl Acad. Sci. USA 2003, 100(23):13225-13230.
188. Shilatifard A. Chromatin modifications by methylation and ubiquitination: Implications in the regulation of gene expression. Annu. Rev. Biochem. 2006, 75:243-269.
189. Smith E.R., Cayrou C., Huang R., Lane W.S., Cote J., Lucchesi J.C. A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol. Cell. Biol. 2005, 25(21):9175-9188.
190. So C.W., Karsunky H., Wong P., Weissman I.L., Cleary M.L. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 2004, 103(8):3192-3199.
191. Somoza J.R., Skene R.J., Katz B.A., Mol C., Ho J.D., Jennings A.J., Luong C., Arvai A., Buggy J.J., Chi E., et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004, 12(7):1325-1334.
192. Song J., Noh J.H., Lee J.H., Eun J.W., Ahn Y.M., Kim S.Y., Lee S.H., Park W.S., Yoo N.J., Lee J.Y., et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005, 113(4):264-268.
193. Spannhoff A., Machmur R., Heinke R., Trojer P., Bauer I., Brosch G., Schule R., Hanefeld W., Sippl W., Jung M. A novel arginine methyltransferase inhibitor with cellular activity. Bioorg. Med. Chem. Lett. 2007, 17(15):4150-4153.
194. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 2006, 6(11):846-856.
195. Spurling C.C., Godman C.A., Noonan E.J., Rasmussen T.P., Rosenberg D.W., Giardina C. HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol. Carcinog. 2008, 47(2):137-147.
196. Stadler W.M., Margolin K., Ferber S., McCulloch W., Thompson J.A. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 2006, 5(1):57-60.
197. Steele-Perkins G., Fang W., Yang X.H., Van Gele M., Carling T., Gu J., Buyse I.M., Fletcher J.A., Liu J., Bronson R., et al. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev. 2001, 15(17):2250-2262.
198. Sterner D.E., Berger S.L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 2000, 64(2):435-459.
199. Stimson L., Wood V., Khan O., Fotheringham S., La Thangue N.B. HDAC inhibitor-based therapies and haematological malignancy. Ann. Oncol. 2009, 20(8):1293-1302.
200. Sun Y., Jiang X., Chen S., Fernandes N., Price B.D. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc. Natl Acad. Sci. USA 2005, 102(37):13182-13187.
201. Sun Y., Jiang X., Chen S., Price B.D. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Lett. 2006, 580(18):4353-4356.
202. Taipale M., Rea S., Richter K., Vilar A., Lichter P., Imhof A., Akhtar A. hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol. Cell. Biol. 2005, 25(15):6798-6810.
203. Tan J., Yang X., Zhuang L., Jiang X., Chen W., Lee P.L., Karuturi R.K., Tan P.B., Liu E.T., Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007, 21(9):1050-1063.
204. Thiagalingam S., Cheng K.H., Lee H.J., Mineva N., Thiagalingam A., Ponte J.F. Histone deacetylases: Unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci. 2003, 983:84-100.
205. Trievel R.C. Structure and function of histone methyltransferases. Crit. Rev. Eukaryot. Gene Expr. 2004, 14(3):147-169.
206. Tsuji N., Kobayashi M., Nagashima K., Wakisaka Y., Koizumi K. A new antifungal antibiotic, trichostatin. J. Antibiot. (Tokyo) 1976, 29(1):1-6.
207. Tsukada Y., Fang J., Erdjument-Bromage H., Warren M.E., Borchers C.H., Tempst P., Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006, 439(7078):811-816.
208. Ungerstedt J.S., Sowa Y., Xu W.S., Shao Y., Dokmanovic M., Perez G., Ngo L., Holmgren A., Jiang X., Marks P.A. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 2005, 102(3):673-678.
209. van Haaften G., Dalgliesh G.L., Davies H., Chen L., Bignell G., Greenman C., Edkins S., Hardy C., O'Meara S., Teague J., et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 2009, 41(5):521-523.
210. Verdin E., Dequiedt F., Kasler H.G. Class II histone deacetylases: Versatile regulators. Trends Genet. 2003, 19(5):286-293.
211. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.M., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439(7078):871-874.
212. Wade P.A., Pruss D., Wolffe A.P. Histone acetylation: Chromatin in action. Trends Biochem. Sci. 1997, 22(4):128-132.
213. Wang J., Hoshino T., Redner R.L., Kajigaya S., Liu J.M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl Acad. Sci. USA 1998, 95(18):10860-10865.
214. Wang Z., Zang C., Rosenfeld J.A., Schones D.E., Barski A., Cuddapah S., Cui K., Roh T.Y., Peng W., Zhang M.Q., et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat. Genet. 2008, 40(7):897-903.
215. Wang Y., Zhang H., Chen Y., Sun Y., Yang F., Yu W., Liang J., Sun L., Yang X., Shi L., et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009, 138(4):660-672.
216. Wang Z., Zang C., Cui K., Schones D.E., Barski A., Peng W., Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009, 138(5):1019-1031.
217. Warrell R.P., Frankel S.R., Miller W.H., Scheinberg D.A., Itri L.M., Hittelman W.N., Vyas R., Andreeff M., Tafuri A., Jakubowski A., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J. Med. 1991, 324(20):1385-1393.
218. Whitehead R.P., Rankin C., Hoff P.M., Gold P.J., Billingsley K.G., Chapman R.A., Wong L., Ward J.H., Abbruzzese J.L., Blanke C.D. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: A Southwest Oncology Group study (S0336). Invest New Drugs 2009, 27(5):469-475.
219. Yamane K., Tateishi K., Klose R.J., Fang J., Fabrizio L.A., Erdjument-Bromage H., Taylor-Papadimitriou J., Tempst P., Zhang Y. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol. Cell 2007, 25(6):801-812.
220. Yan Y., Barlev N.A., Haley R.H., Berger S.L., Marmorstein R. Crystal structure of yeast Esa1 suggests a unified mechanism for catalysis and substrate binding by histone acetyltransferases. Mol. Cell 2000, 6(5):1195-1205.
221. Yang X.J., Seto E. The Rpd3/Hda1 family of lysine deacetylases: From bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 2008, 9(3):206-218.
222. Yang X.J., Ogryzko V.V., Nishikawa J., Howard B.H., Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996, 382(6589):319-324.
223. Yoshida M., Hoshikawa Y., Koseki K., Mori K., Beppu T. Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J. Antibiot. (Tokyo) 1990, 43(9):1101-1106.
224. Zeidler M., Varambally S., Cao Q., Chinnaiyan A.M., Ferguson D.O., Merajver S.D., Kleer C.G. The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia 2005, 7(11):1011-1019.
225. Zeleznik-Le N.J., Harden A.M., Rowley J.D. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc. Natl Acad. Sci. USA 1994, 91(22):10610-10614.
226. Ziemin-van der Poel S., McCabe N.R., Gill H.J., Espinosa R., Patel Y., Harden A., Rubinelli P., Smith S.D., LeBeau M.M., Rowley J.D., et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc. Natl. Acad. Sci. USA 1991, 88(23):10735-10739.
227. Zimra Y., Nudelman A., Zhuk R., Rabizadeh E., Shaklai M., Aviram A., Rephaeli A. Uptake of pivaloyloxymethyl butyrate into leukemic cells and its intracellular esterase-catalyzed hydrolysis. J. Cancer Res. Clin. Oncol. 2000, 126(12):693-698.